Zenas BioPharma Q3 EPS Estimate Decreased by HC Wainwright

Key Points

• HC Wainwright has lowered earnings estimates for Zenas BioPharma, projecting a Q3 2025 EPS of ($1.08), down from a previous estimate of ($0.93).
• The company reported its latest earnings on August 12, missing the consensus estimate, with an EPS of ($1.25).
• Despite this, HC Wainwright maintains a "Buy" rating for the stock with a price target of $30.00.

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) - Equities researchers at HC Wainwright dropped their Q3 2025 earnings per share estimates for Zenas BioPharma in a report released on Wednesday, August 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($1.08) per share for the quarter, down from their previous estimate of ($0.93). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. HC Wainwright also issued estimates for Zenas BioPharma's Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.17) EPS, FY2026 earnings at ($3.69) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.85) EPS and FY2029 earnings at ($1.87) EPS.

A number of other equities analysts have also issued reports on ZBIO. Wall Street Zen lowered shares of Zenas BioPharma from a "hold" rating to a "sell" rating in a research report on Saturday. Wedbush restated an "outperform" rating and set a $35.00 target price on shares of Zenas BioPharma in a report on Thursday, May 15th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $36.67.

Zenas BioPharma Price Performance

Shares of ZBIO traded down $0.34 during trading hours on Friday, reaching $15.51. 59,872 shares of the company's stock traded hands, compared to its average volume of 180,200. Zenas BioPharma has a twelve month low of $5.83 and a twelve month high of $26.25. The stock has a fifty day simple moving average of $12.92. The company has a market cap of $653.13 million and a price-to-earnings ratio of -4.37.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund bought a new stake in shares of Zenas BioPharma in the 1st quarter valued at approximately $49,000. PNC Financial Services Group Inc. grew its holdings in Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after purchasing an additional 2,679 shares during the last quarter. Sei Investments Co. bought a new position in shares of Zenas BioPharma in the second quarter valued at approximately $118,000. Intech Investment Management LLC lifted its stake in shares of Zenas BioPharma by 13.9% in the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company's stock worth $128,000 after buying an additional 1,607 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Zenas BioPharma by 32.3% during the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock worth $136,000 after buying an additional 3,412 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.